DRAVP ID  DRAVPc057

Name   Glecaprevir

Sequence  Not available

Molecular Formula  C38H46F4N6O9S

Condition/Disease  Chronic HCV infection

Group  Approved

Type  Peptide like Small molecule

Description  Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

Active sequence/Structure 

No comments found

DrugBank Accession Number  DB13879

Pubchem ID  66828839

CHEMBL ID  CHEMBL3545363

UNII  K6BUU8J72P

CAS  1365970-03-1

Reference  24282816  36466430